Does the media favor PCRX or NMRA?

In the previous week, Pacira BioSciences had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Neumora Therapeutics. Pacira BioSciences' average media sentiment score of 1.66 beat Neumora Therapeutics' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NMRA or IVA?

Neumora Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Inventiva $5.07M 198.29 -$400.67M N/A N/A

Is NMRA or IVA more profitable?

Inventiva's return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Inventiva N/A N/A N/A

Does the media refer more to NMRA or IVA?

In the previous week, Inventiva had 7 more articles in the media than Neumora Therapeutics. MarketBeat recorded 8 mentions for Inventiva and 1 mentions for Neumora Therapeutics. Inventiva's average media sentiment score of 0.13 beat Neumora Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NMRA or ARDX?

In the previous week, Ardelyx had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Ardelyx and 1 mentions for Neumora Therapeutics. Ardelyx's average media sentiment score of 0.65 beat Neumora Therapeutics' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NMRA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 1 mentions for Neumora Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.97 beat Neumora Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NMRA or GLAS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Glass House Brands N/A N/A N/A N/A N/A

Is NMRA or GLAS more profitable?

Glass House Brands' return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Glass House Brands N/A N/A N/A

Does the media refer more to NMRA or GLAS?

In the previous week, Glass House Brands had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Glass House Brands and 1 mentions for Neumora Therapeutics. Glass House Brands' average media sentiment score of 0.38 beat Neumora Therapeutics' score of 0.00 indicating that Glass House Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neumora Therapeutics (NMRA) Competitors

$1.35 -0.03 (-2.17%)

As of 09/3/2026 04:00 PM Eastern

Compare

NMRA vs. PCRX, IVA, ARDX, AMPH, and GLAS

Should you buy Neumora Therapeutics stock or one of its competitors? Neumora Therapeutics's main competitors and comparable companies include Pacira BioSciences (PCRX), Inventiva (IVA), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), and Glass House Brands (GLAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neumora Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Pacira BioSciences has a net margin of 1.96% compared to Neumora Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Pacira BioSciences has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Pacira BioSciences presently has a consensus target price of $30.20, indicating a potential upside of 13.53%. Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 386.77%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Pacira BioSciences has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.46	$7.03M	$0.35	76.00
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pacira BioSciences had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Neumora Therapeutics. Pacira BioSciences' average media sentiment score of 1.66 beat Neumora Therapeutics' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pacira BioSciences beats Neumora Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Inventiva?

Neumora Therapeutics (NASDAQ:NMRA) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

In the previous week, Inventiva had 7 more articles in the media than Neumora Therapeutics. MarketBeat recorded 8 mentions for Inventiva and 1 mentions for Neumora Therapeutics. Inventiva's average media sentiment score of 0.13 beat Neumora Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Inventiva	N/A	N/A	N/A

Neumora Therapeutics currently has a consensus target price of $6.57, indicating a potential upside of 386.77%. Inventiva has a consensus target price of $15.38, indicating a potential upside of 217.67%. Given Neumora Therapeutics' higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Neumora Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Inventiva	$5.07M	198.29	-$400.67M	N/A	N/A

Summary

Inventiva beats Neumora Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Neumora Therapeutics compare to Ardelyx?

Neumora Therapeutics (NASDAQ:NMRA) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Neumora Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Neumora Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Ardelyx	-12.35%	-36.00%	-10.77%

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ardelyx has higher revenue and earnings than Neumora Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Ardelyx	$407.32M	2.27	-$61.60M	-$0.22	N/A

In the previous week, Ardelyx had 5 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Ardelyx and 1 mentions for Neumora Therapeutics. Ardelyx's average media sentiment score of 0.65 beat Neumora Therapeutics' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics presently has a consensus price target of $6.57, indicating a potential upside of 386.77%. Ardelyx has a consensus price target of $13.90, indicating a potential upside of 274.66%. Given Neumora Therapeutics' higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Ardelyx beats Neumora Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Amphastar Pharmaceuticals?

Neumora Therapeutics (NASDAQ:NMRA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Amphastar Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Amphastar Pharmaceuticals	$719.89M	1.41	$98.09M	$1.69	14.11

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Neumora Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 386.77%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential downside of 5.62%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 1 mentions for Neumora Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.97 beat Neumora Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Neumora Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Glass House Brands?

Neumora Therapeutics (NASDAQ:NMRA) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Glass House Brands had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Glass House Brands and 1 mentions for Neumora Therapeutics. Glass House Brands' average media sentiment score of 0.38 beat Neumora Therapeutics' score of 0.00 indicating that Glass House Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Glass House Brands' return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Glass House Brands	N/A	N/A	N/A

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 386.77%. Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 86.70%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neumora Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neumora Therapeutics beats Glass House Brands on 6 of the 10 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$259.30M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.10	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	5.63	12.33	12.89	6.14
Net Income	-$236.93M	$2.82B	$3.47B	$349.01M
7 Day Performance	-2.88%	2.59%	0.60%	-0.27%
1 Month Performance	-15.63%	6.95%	5.73%	0.68%
1 Year Performance	-17.18%	9.45%	25.35%	14.84%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	1.969 of 5 stars	$1.35 -2.2%	$6.57 +386.8%	-22.9%	$259.30M	N/A	N/A	108
PCRX Pacira BioSciences	3.5474 of 5 stars	$25.90 +0.5%	$30.20 +16.6%	-2.1%	$1.03B	$726.41M	74.00	720	Positive News Analyst Upgrade
IVA Inventiva	2.3069 of 5 stars	$4.68 -0.4%	$15.38 +228.5%	-16.1%	$977.26M	$5.07M	N/A	100	Gap Up
ARDX Ardelyx	3.9985 of 5 stars	$3.78 -0.8%	$13.90 +267.7%	-43.0%	$949.41M	$407.32M	N/A	90
AMPH Amphastar Pharmaceuticals	1.8456 of 5 stars	$22.53 +2.4%	$22.50 -0.1%	-18.9%	$936.26M	$719.89M	13.33	1,976

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. PCRX, IVA, ARDX, AMPH, and GLAS

How does Neumora Therapeutics compare to Pacira BioSciences?

Summary

How does Neumora Therapeutics compare to Inventiva?

Summary

How does Neumora Therapeutics compare to Ardelyx?

Summary

How does Neumora Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Neumora Therapeutics compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. PCRX, IVA, ARDX, AMPH, and GLAS

How does Neumora Therapeutics compare to Pacira BioSciences?

Is PCRX or NMRA more profitable?

Which has more volatility & risk, PCRX or NMRA?

Do analysts recommend PCRX or NMRA?

Which has preferable earnings and valuation, PCRX or NMRA?

Do institutionals and insiders have more ownership in PCRX or NMRA?

Does the media favor PCRX or NMRA?

Summary

How does Neumora Therapeutics compare to Inventiva?

Do insiders & institutionals hold more shares of NMRA or IVA?

Which has more volatility & risk, NMRA or IVA?

Does the media refer more to NMRA or IVA?

Is NMRA or IVA more profitable?

Do analysts rate NMRA or IVA?

Which has higher earnings & valuation, NMRA or IVA?

Summary

How does Neumora Therapeutics compare to Ardelyx?

Which has more risk & volatility, NMRA or ARDX?

Is NMRA or ARDX more profitable?

Do institutionals and insiders hold more shares of NMRA or ARDX?

Which has higher valuation and earnings, NMRA or ARDX?

Does the media favor NMRA or ARDX?

Do analysts prefer NMRA or ARDX?

Summary

How does Neumora Therapeutics compare to Amphastar Pharmaceuticals?

Which has preferable earnings and valuation, NMRA or AMPH?

Do institutionals & insiders hold more shares of NMRA or AMPH?

Is NMRA or AMPH more profitable?

Do analysts recommend NMRA or AMPH?

Which has more risk & volatility, NMRA or AMPH?

Does the media favor NMRA or AMPH?

Summary

How does Neumora Therapeutics compare to Glass House Brands?

Which has better earnings & valuation, NMRA or GLAS?

Do institutionals and insiders have more ownership in NMRA or GLAS?

Does the media refer more to NMRA or GLAS?

Is NMRA or GLAS more profitable?

Do analysts prefer NMRA or GLAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools